AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Impact · against what's priced in

Apogee Therapeutics is a direct buyout target, leading to a significant positive valuation adjustment. AbbVie is expanding its immunology pipeline via a $10.9 billion cash acquisition to mitigate long-term portfolio risk.

APOG+1.00: No priced-in read yet
In context: The company is being acquired for approximately $10.9 billion in cash, providing an immediate and certain valuation floor.
Read from the article alone
Actual

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

m and a
healthcare
ABBV
APOG
acquisition
biopharma
immunology

Search tags

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

What matters in this story

PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

What matters in this story

PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger

How each ticker is affected

Connected tickers

Track these names every morning.

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Gilead to Report Q3 Earnings: How Should You Play the Stock Now?

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?

IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

What matters in this story

Next reads from the same story arc

PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

What matters in this story

Next reads from the same story arc

PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger

How each ticker is affected

Connected tickers

Track these names every morning.

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Gilead to Report Q3 Earnings: How Should You Play the Stock Now?

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?

IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y